OncoCyte (NASDAQ:OCX) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX) in a research note issued to investors on Monday morning. The brokerage issued a sell rating on the stock.

OCX has been the topic of several other research reports. Benchmark reaffirmed a speculative buy rating and issued a $5.00 price target on shares of OncoCyte in a report on Monday, April 15th. Needham & Company LLC reissued a buy rating and issued a $4.25 price target on shares of OncoCyte in a research note on Thursday, May 16th. Finally, Stephens reissued an equal weight rating and issued a $4.00 target price on shares of OncoCyte in a research note on Wednesday, April 17th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of Hold and an average price target of $4.06.

OncoCyte Stock Performance

NASDAQ:OCX opened at $2.76 on Monday. OncoCyte has a 52-week low of $2.08 and a 52-week high of $4.86. The business’s fifty day moving average is $2.72 and its 200 day moving average is $2.94.

OncoCyte (NASDAQ:OCX) last released its quarterly earnings data on Wednesday, May 15th. The company reported ($1.13) EPS for the quarter. OncoCyte had a negative net margin of 2,905.14% and a negative return on equity of 135.45%. The firm had revenue of $0.18 million during the quarter. Research analysts forecast that OncoCyte will post -2.58 earnings per share for the current year.

Insider Activity

In other OncoCyte news, Director Andrew Arno purchased 33,898 shares of the stock in a transaction on Thursday, April 11th. The stock was acquired at an average cost of $2.95 per share, with a total value of $99,999.10. Following the completion of the purchase, the director now directly owns 69,054 shares of the company’s stock, valued at approximately $203,709.30. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Andrew Arno bought 33,898 shares of the business’s stock in a transaction dated Thursday, April 11th. The shares were purchased at an average price of $2.95 per share, for a total transaction of $99,999.10. Following the completion of the acquisition, the director now owns 69,054 shares of the company’s stock, valued at $203,709.30. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Broadwood Partners, L.P. bought 2,420,000 shares of the firm’s stock in a transaction that occurred on Thursday, April 11th. The stock was purchased at an average cost of $2.92 per share, for a total transaction of $7,066,400.00. Following the completion of the purchase, the insider now owns 4,929,066 shares of the company’s stock, valued at $14,392,872.72. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 2,457,288 shares of company stock valued at $7,176,400. Corporate insiders own 1.94% of the company’s stock.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.